Study guide

16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders

Certified Addictions Registered Nurse - Advanced Practice CARN-AP

Track your progress as you read

Finished sections get a check mark.

1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice

About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care

2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance

1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene

3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone

2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)

4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal

3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications

5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)

4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen

6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders

5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds

7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions

6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management

8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions

7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice

9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning

8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy

10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines

9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)

11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications

10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP

12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing

11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation

13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy

12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine

14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction

13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education

15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition

14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol

16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder

15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support

17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations

16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders

18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy

17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education

19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse

18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM

20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)

19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching

21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)

20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation

22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)

21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction

16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders

Key Takeaways Explain This Topic AI

The EAGLES trial enrolled 8,144 smokers including a psychiatric cohort of 4,116 and found no significant increase in serious neuropsychiatric events with varenicline or bupropion relative to patch or placebo.

Tobacco smoke induces CYP1A2, so quitting raises clozapine and olanzapine levels and can require dose reductions of roughly 30 to 40 percent with monitoring.

Behavioral counseling is first-line in pregnancy, and financial incentives have the strongest evidence among behavioral strategies for pregnant smokers.

Varenicline is the most effective single agent for most smokers and remains effective in people with serious mental illness and in people in addiction treatment.

Combination nicotine replacement using a patch plus an as-needed short-acting product outperforms any single nicotine replacement product.

Last updated: September 2026

16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders

Quick Answer: EAGLES (N = 8,144, including a psychiatric cohort of 4,116) found no significant increase in moderate-to-severe neuropsychiatric events with varenicline or bupropion versus nicotine patch or placebo, and led the FDA to remove the boxed warning. Smoking induces CYP1A2 , so cessation raises clozapine and olanzapine concentrations — plan a dose reduction with level monitoring. In pregnancy , behavioral counseling is first line and financial incentives have the strongest behavioral evidence. Combination NRT (patch plus a short-acting product) beats any single NRT product.

1. Serious Mental Illness

Issue Clinical response

Very high prevalence and heavy consumption Screen and treat at every contact; do not defer to "when they are more stable"

Neuropsychiatric safety concerns EAGLES resolved these for varenicline and bupropion; monitor mood as you would with any change, but do not withhold effective medication

CYP1A2 induction by polycyclic aromatic hydrocarbons in smoke On cessation, clozapine and olanzapine levels rise; a reduction of roughly 30 to 40 percent with level monitoring is commonly needed. This is caused by smoke , not nicotine — switching to NRT or vaping does not prevent the interaction

Other affected agents Also relevant for fluvoxamine, duloxetine, theophylline, caffeine and, to a lesser degree, haloperidol

Bupropion caution Lowers seizure threshold; avoid with eating disorder history or abrupt sedative withdrawal; has mild antidepressant effect that can be useful

Negative symptoms and cognition Patients often smoke to self-manage; substitute explicit skills and structure rather than leaving a void

Exam trap: the most frequently missed item in this area is that the clozapine interaction is caused by combustion products , not nicotine. A patient who switches entirely from cigarettes to the patch still loses the CYP1A2 induction and still needs the dose review.

2. Concurrent Alcohol and Other Drug Use Disorders

Smoking prevalence in addiction treatment populations remains dramatically elevated, and tobacco is a leading killer of people who successfully stop drinking or using opioids.

Alcohol is the most common single trigger for first-week smoking relapse. Plan for it explicitly.

Concurrent treatment improves substance use outcomes; the widespread belief to the contrary is unsupported.

Varenicline has an additional signal for reduced heavy drinking in some trials, which can be raised as a secondary benefit with patients who have alcohol use disorder.

Patients in opioid treatment programs smoke at extremely high rates and are a captive, under-served population for whom on-site tobacco treatment is high yield.

3. Pregnancy and Postpartum

  • Element Recommendation
  • First line Intensive behavioral counseling, ideally more than the minimal contact used in general populations

Strongest behavioral evidence Financial incentives , which have the largest effect of any behavioral strategy in pregnancy

Pharmacotherapy Evidence is limited; NRT may be considered when behavioral treatment fails and the patient continues to smoke, after an explicit risk-benefit discussion. Intermittent forms allow lower total daily exposure; some clinicians prefer them for that reason

  • Varenicline and bupropion Data in pregnancy are limited; generally not first line
  • Postpartum Relapse rates are very high in the first six months; schedule proactive contact rather than waiting

Secondhand exposure Counsel on complete home and vehicle smoking bans; "smoking on the porch" leaves thirdhand residue on clothing and surfaces

4. Adolescents

Behavioral interventions are first line; pharmacotherapy evidence in adolescents is limited and NRT is used selectively in heavily dependent youth.

Nicotine-salt pod systems deliver high nicotine efficiently, and dependence can develop quickly; ask about vaping explicitly, since many adolescents do not consider it "smoking."

Flavors and menthol drive initiation; social media marketing is a major exposure route.

Confidentiality and family engagement must be balanced according to state minor-consent law.

5. Cardiovascular and Perioperative Patients

NRT is safe in stable cardiovascular disease , including after myocardial infarction, and is far safer than continued smoking. The older blanket contraindication has not survived the evidence.

Hospitalization for an acute cardiac event is a teachable moment with unusually high quit success; start treatment in hospital and arrange follow-up within one week of discharge, because inpatient-only intervention loses most of its effect.

Preoperative cessation reduces wound infection and pulmonary complications; benefit increases with longer preoperative abstinence but is measurable even at shorter intervals.

6. Choosing an Agent: A Compact Decision Aid

Situation First choice Rationale

Most smokers, no contraindication Varenicline Highest single-agent efficacy; EAGLES supports safety in psychiatric populations

Patient declines varenicline or it is unavailable Combination NRT (patch plus gum, lozenge, inhaler or spray) Outperforms any single NRT product

Co-occurring depression or weight concern Bupropion , alone or with NRT Antidepressant effect and attenuation of post-cessation weight gain

Seizure disorder or eating-disorder history Avoid bupropion ; use varenicline or combination NRT Seizure risk

Severe renal impairment Varenicline at reduced dose (0.5 mg daily, maximum 0.5 mg twice daily) Predominantly renal elimination

Pregnancy Behavioral counseling plus incentives; NRT only after risk-benefit discussion Limited pharmacotherapy safety data